Technology

Pharma-Scale HTS Organ-on-Chip Powered by Image-Based AI for More Predictive Modeling

Organ-on-Chip Technology + Multicellular 3D Disease Model Development and Artificial Intelligence provides spatiotemporal profiling and analysis of drug testing and treatment at a cellular level.

Our microfluidic-based Organ-on-Chip technology recapitulates the multicellular microenvironment of the organ, providing an excellent in vitro model suitable for drug discovery. 

Spatially controlled distribution of hydrogel and perfusion channel

Barrierless Design
No barrier between the ECM and perfusion channels

Paracrine signaling experienced in vivo

Downstream morphological, secretory, and multi-omics profiling of these complex organ models using AI and machine learning analysis, allows the development of multiplexed profiles of different cellular populations, permitting the detection of subtle biologically relevant responses and phenotypes.

Data Science & AI Platform

Our Data Science and AI Platform provides downstream morphological, secretory, and multi-omics profiling of complex organ models using AI and machine learning analysis, enabling the development of multiplexed profiles of different cellular populations, permitting the detection of subtle biologically relevant responses and phenotypes.

Organ-on-Chip Technology

Our organ-on-chip technology has demonstrated cost and time savings while better replicating human physiological conditions.  Current methods, including 2D Cell Culture, 3D Cell Culture and Animal Models have proven limitations when compared to Organ-on-Chip platforms.

ADVANTAGES

  • High throughput Simple operation
  • Suitable for research applications

 

LIMITATIONS

  • Challenging to construct
  • Physiological state of immortalized cell lines
  • Absence of specific organ microenvironment
    Inability to predict drug sensitivity
  • Absence of vascular system
  • Poor reproducibility in culture

ADVANTAGES

  • Retains in vivo tumor characteristics
  • Predicts drug sensitivity

 

LIMITATIONS

  • Excessive duration, 4–8 months
  • Requires animal housing, resulting in higher costs
  • Requires large quantities of tumor tissue
  • Low success rate in certain tumor types
  • Difficulty in procuring laboratory animals
    Lack of reproducibility

ADVANTAGES

  • Preserves the thermal characteristics of in vivo tumors
  • Predicts drug sensitivity
  • High throughput
  • Lower cost than PDX
  • High construction success rate Short turnaround time
  • Requires minimal tumor tissue

 

LIMITATIONS

  • Semi-physiological state
  • Lacks vascularization system
  • Static culture
  • Simulates the in
    vivo microenvironment
  • Simulates in vivo physiological and pathological characteristics
  • Simulates tissue barriers, vascular-ization, and immune system
  • High construction success rate Low sample volume requirement
  • Enables investigation of intercellu-lar interactions
  • Real-time imaging and status moni-toring
  • Dynamic culture

For Example, Our Liver-On-Chip Model Demonstrates High Predictive Accuracy for DILI vs. Traditional Models

We Are Leading a Worldwide Effort to Accelerate the Adoption of Organ Chip Technology in the Regulatory Framework

Proof-of-Concept

Establish new disease models for research and drug testing applications

Technical Validation

Perform technical validation and multi-center validation to build confidence in the model’s predictive performance, data quality, and robustness

Qualification

Establish guidelines and standards to incorporate Organ Chip and AI technologies in regulatory submission and approval

Adoption

Promote the use of Organ Chip Models in Safety Assessment and Precision Medicine

Back
outreach@xellarbio.com
Viber
WhatsApp
Twitter
Linkedin

Contact Us

Leave us a request and we will contact you soon.